Kathryn Sykes

Kathryn Sykes, PhD, has over 20 years of experience developing innovative molecular and chemical technologies to manipulate the immune system toward better health. While a co-founder of the cancer vaccine company Calviri, she is also the VP of Research at HealthTell, Inc., which is developing global measurements of immune health. Previously, she was an Assistant Professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. There her research focused on inventing molecular, bead and array-based approaches to enable novel vaccine discovery against infectious and chronic diseases At the University of Texas Southwestern Medical she pursued technologies that became the basis of a Texas biotechnology company that was ultimately acquired by MacroGenics, Inc. As their Director of Research, she implemented high-throughput, synthetic methods for genetic engineering and combinatorial screening toward discovery of new protective antigens. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry from Duke University Medical Center.